Agree Realty Declares Monthly Cash Dividend
- Wall Street ends week positively; S&P 500, Dow hit record highs
- Bitcoin (BTC) Drops 3% as Turkey Bans Cryptocurrency Payments Citing Lack of Regulatory Supervision
- Morgan Stanley (MS) Archegos-Related Loss Appears to be $911M
- Dollar at 4-week low on retreating Treasury yields
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
BLOOMFIELD HILLS, Mich., Feb. 11, 2021 /PRNewswire/ -- Agree Realty Corporation (NYSE: ADC) (the "Company") today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividend of $0.207 per common share. The monthly dividend reflects an annualized dividend amount of $2.484 per common share, representing a 6.2% increase over the annualized dividend amount of $2.340 per common share from the first quarter of 2020. The dividend is payable March 12, 2021 to stockholders of record at the close of business on February 26, 2021.
About Agree Realty Corporation
Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of December 31, 2020, the Company owned and operated a portfolio of 1,129 properties, located in 46 states and containing approximately 22.7 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol "ADC". For additional information, please visit www.agreerealty.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/agree-realty-declares-monthly-cash-dividend-301226907.html
SOURCE Agree Realty Corporation
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Former Andrews McMeel Universal Vice Chairman and Andrews McMeel Publishing CEO Kathleen Andrews Dies
- Peloton Refutes Consumer Product Safety Commission Claims
- Autobahn Therapeutics Presents Preclinical, Proof of Concept Data for ABX-002 for the Treatment of Adrenomyeloneuropathy